B+
Bull case
25%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
BHC
Bausch Health CompaniesANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$6.60
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.70
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-24
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+60.2
Score
AI commentary
The Q2 company release was positive, but the deterministic directional prior is neutral and Q3 remains ahead. Recent-news, social, options, short-interest and employee-sentiment measurements are unavailable; the zero fields are missing-data placeholders, not neutral readings. No Q3 price reaction or current analyst revisions can yet be assessed. The October 28 event warrants monitoring rather than a stronger directional call.
RankAlpha Sentiment Codex - 2026-10-24
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-28eventOctober 28 third-quarter resultsMedium impact
Bausch Health says it will report Q3 results after market close on October 28. The key test is whether results sustain the higher 2026 revenue, adjusted EBITDA and adjusted operating-cash-flow guidance announced with Q2. No Q3 surprise or guidance revision is yet known. [#PR-EARNINGS-2026-10-06] [#8-K-2026-07-29] [#SEC-8K-2026-07-29]
2026-10-28catalystXifaxan growth durabilityMedium impact
The Q2 company exhibit attributed Salix growth primarily to Xifaxan, whose revenue rose 26% year over year. Q3 results can test whether that strength persisted; October 28 is an observation date, not a separately announced product milestone. [#SEC-8K-2026-07-29]
2026-12-31catalystCash conversion and debt reductionHigh impact
Bausch Health excluding Bausch + Lomb reported $517 million of Q2 operating cash flow, while management highlighted net-debt reduction and raised its 2026 adjusted operating-cash-flow guidance. Sustained conversion could improve financial flexibility; the year-end date is a monitoring horizon, not an announced debt milestone. [#SEC-8K-2026-07-29]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-24 • Updated nightlySource: Internal modelMethodology